Tag

Galleri

All articles tagged with #galleri

health1 month ago•6 min saved

Multi-Cancer Blood Tests: Promise Hangs in the Balance

Researchers are pursuing multi-cancer blood tests using DNA fragments and AI, with early signals like Mercury showing notable sensitivity across several cancers. Yet the largest Galleri trial did not reduce advanced cancer diagnoses or provide clear survival benefits, and test accuracy varies by cancer type. Experts say a universal one-test solution is unlikely; a portfolio of targeted tests and longer follow-up to prove life-saving value and enable insurer coverage is more plausible before routine use.

via NBC News|

#blood-test #cancer #galleri

health1 month ago•13 min saved

Testing the Promise: My Take on the Galleri Cancer Blood Test

A first-person look at Grail’s Galleri multi-cancer early detection blood test: the $824 home draw returned no cancer signal, but real-world results are mixed and medical groups remain cautious, with limited evidence of mortality benefit and concerns about false positives and missed cancers. While some see potential, experts emphasize that MRI scans or traditional symptom-driven screening remain more established, and readers are advised to discuss symptoms with a doctor and not rely on MCED tests as a sole screening tool.

via Business Insider|

#at-home-testing #cancer-screening #galleri

health2 months ago•12 min saved

The bold promise of multi-cancer blood tests hits real-world limits

Multi-cancer early detection (MCED) blood tests, including Galleri, promise to detect dozens of cancers from one blood sample, but few have robust randomized trial data; the NHS-backed Galleri trial failed to show improved outcomes in reducing late-stage cancers, and while tests boast high specificity, sensitivity varies and the risk of false positives can lead to anxiety and unnecessary follow-ups, leaving regulators and clinicians cautious until stronger evidence accumulates.

via Nature|

#cancer-screening #galleri #health

healthcare3 months ago•2 min saved

Grail stock slumps after NHS Galleri trial misses primary endpoint

Grail's stock fell more than 45% after-hours after NHS-Galleri trial failed to meet its primary endpoint, showing no statistically significant reduction in later-stage cancers overall; however, a pre-specified group of 12 deadly cancers showed a favorable trend toward fewer stage III-IV cancers, with greater reductions in stage IV diagnoses across sequential screening rounds. The company will extend follow-up by 6-12 months to seek stronger effects, and it also reported 17% full-year revenue growth to $147.2 million, with U.S. Galleri revenue up 26% to $136.8 million.

via Fierce Biotech|

#clinical-trials #galleri #grail

health3 months ago•3 min saved

Major UK Trial Undermines Promise of Galleri Multi-Cancer Blood Test

In a large UK trial of 142,000 adults over three years, Grail's Galleri multi-cancer blood test did not reduce late-stage cancers (stages 3–4), though researchers noted a secondary signal of fewer Stage 4 cancers; the test remains FDA-unapproved, is sold with limited insurer coverage, and Medicare coverage remains under legislative review.

via The New York Times|

#cancer-detection #clinical-trial #galleri

biotech3 months ago•2 min saved

Grail's Galleri multi-cancer test misses primary endpoint in NHS study, fueling skepticism

Grail's Galleri blood test for early cancer detection failed to meet its primary endpoint in a large NHS-backed study, renewing questions about its clinical utility despite some detected benefits. Grail reported selling 185,000 tests in 2025 for $136.8 million, and its stock fell about 47% after hours following the setback.

via statnews.com|

#biotech #cancer-detection #diagnostics

health6 months ago•5 min saved

I Tried the Blood Test That Detects 50 Types of Cancer

The article discusses the Galleri multi-cancer early detection blood test, which studies DNA fragments to detect 50 types of cancer, highlighting its potential, limitations, and the author's personal experience with a negative result, emphasizing that it is not a replacement for existing screenings but a promising supplement.

via Yahoo News Canada|

#blood-test #cancer-detection #early-detection

health7 months ago•2 min saved

Revolutionary Blood Test Detects Over 50 Cancers Early, Boosting Screening Effectiveness

A new blood test called Galleri, capable of detecting over 50 types of cancer, shows promising results in early detection, especially for cancers without existing screening programs, potentially transforming cancer diagnosis and treatment. However, further research is needed to confirm its impact on mortality and avoid overdiagnosis.

via BBC|

#blood-test #cancer #early-detection

health10 months ago•7 min saved

Rush Launches Blood Test to Detect Over 50 Cancers Amid Industry Hesitation

Rush University is now offering the Galleri blood test, which can detect over 50 types of cancer early by identifying cancer DNA in the bloodstream, despite it not yet being FDA-approved. The test has shown promise in clinical trials and could significantly improve early cancer detection, but some health systems remain cautious due to concerns about accuracy, cost, and regulatory approval.

via Chicago Tribune|

#blood-test #cancer-detection #early-diagnosis

healthscience2 years ago•0 min saved

"Challenges to Grail's Galleri Cancer Liquid Biopsy Evaluation Plan"

WHO scientists are questioning the clinical trial endpoint being used by Grail to evaluate its Galleri blood test, which aims to detect multiple types of tumors early. The test is currently available in the U.S. but not yet approved by the FDA or reimbursed by Medicare, and Grail generated $30 million in revenue in the fourth quarter of 2023 while incurring a $197 million loss. If successful, the Galleri test could revolutionize cancer screening as a multi-cancer early detection test, but concerns about its evaluation process persist.

via STAT|

#cancer-screening #clinical-trial #galleri

healthcare-technology3 years ago•7 min saved

"Grail's Multi-Cancer Blood Test Shows Promise in Large Study"

Grail, a blood testing company, presented the results of a large study at ASCO23, which showed that its commercial blood test, Galleri, could be used to diagnose patients suspected of having cancer due to symptoms such as abdominal pain, rectal bleeding, or unexplained weight loss. The test searches for the genetic fingerprints of cancer in the blood, and Grail hopes that doctors will consider it as an alternative to expensive scans or invasive biopsies.

via Endpoints News|

#asco23 #blood-test #cancer-diagnosis

health3 years ago•1 min saved

Revolutionary Blood Test Detects 50 Types of Cancer.

Grail, a healthcare company, has developed a blood test called Galleri that can detect over 50 types of cancer with a single blood sample. The test has a high predictive rate of 45% and can predict where the cancer is in the body with 90% accuracy. The next step is the NHS-Galleri clinical trial to demonstrate the test's effectiveness at scale.

via WIRED|

#blood-test #cancer #early-detection